Back on October 27th I made a post highlighting a potential reversal as we approached the range lows from back in June. Over the future months the stock tested the lows, found support, and is not heading toward highs. Range highs and lows and major support and resistance areas have value because they indicate where there is likely to be heavy order flow. In this...
AditxtScore™ Immune Monitoring Service Will be Operational on February 1st Company Plans to Offer Service through Channel Partners The initial application of the platform will be AditxtScore™ for COVID-19 which has been designed to provide a more complete assessment of an individual’s infection and immunity status with respect to the SARS-CoV-2 virus. We’re...
Interesting to see Q4 report for ArcticZymes to learn more about the use of their cod enzymes in Covid 19 vaccines
Obalon Therapeutics Surges 75% On News Of Merger With ReShape Lifesciences ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering ReShape Lifesciences, a weight-loss solutions company, entered into a merger agreement with Obalon Therapeutics, under which ReShape and Obalon will combine in an all-stock...
Clean breakout and a lot of heavy hitters own this stock. Long here.
Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA -- FDA sets PDUFA date of July 17, 2021 --
First pullback , second pullback and now we are on the third pullback . That is the actual situation after getting a +93.10% performance over the course of the week. Right now biotechnological and medical stocks are rising because of the news, but be careful on getting into this stock, it might be too late. Usually stocks do not bounce a fourth time after three...
H.C. Wainwright analyst Ram Selvaraju rates SRNE a Buy along with a $30 price target, which implies a 275% upside from current levels. Factors behind the optimistic outlook: 1. Sorrento has a stake in two cell-based immunotherapy companies that could “drive value in Sorrento shares over the coming months.” 2. the analyst highlights Sorrento’s “burgeoning...
Oppenheimer 5-star Analyst Says BioNano Genomics is ready to Execute in 2021. the latest move was decidedly upbeat. In Wednesday’s session, the stock took off to the tune of 40% following the publication of some positive data. article which made side-by-side comparisons between Bionano’s optical genome mapping platform Saphyr and PacBio's HiFi chemistry revealed...
U.S. FDA Lists Applied DNA’s Linea™ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7) (FDA) published a safety communication (the "Communication") that identifies the Company’s Linea™ COVID-19 Assay Kit (the "Assay Kit") as one of only two tests marketed under the FDA’s Emergency Use...
Atara Biotherapeutics , Inc. (Nasdaq: ATRA ), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases "Atara made significant progress in 2020 and is well-positioned for a strong 2021," said...
DBV Technologies Spikes on Positive FDA Communication DBV Technologies received positive responses from the U.S. Food and Drug Administration regarding its application for a peanut allergy treatment. The U.S. FDA provided type A meeting requests to the questions the French company submitted in October following its receipt of a complete response letter in...
Botanix Pharmaceuticals Ltd (ASX:BOT) is a clinical stage cannabinoid therapeutics company. The company focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The...
$GILD is looking bullish going into 2021 We need a breakout of this downtrend channel for the impulsive waves to be valid, look for a break at the red trendline as well as a retest as support in wave 4
Hi Ya'll, I hope you're having a Good Friday night. I came across this gem yesterday and I have to give it a shout out. ObsEva is a unique company, and has lots of potential. They have three drugs currently in pipelines. Its recently broken out and is channeling upward and moving very healthily. I have a price target of $10+. With a long term hold. Yselty- Phase...
My current waves on $MRK would love some feedback, this catalyst and original chart was brought up originally by @tomikazi It broke out of the downtrend channel and now is in wave 1. Has a catalyst on Wednesday 1/20/21 PDUFA VII Decision for MRK's Vericiguat: Merck Seeks Approval For Heart Failure Drug Company: Merck & Co., Inc. (NYSE: MRK) Type of...
$13.2M mkt cap, 3.5M float. Freshly uplisted to NASDAQ. Closed $11M oversubscribed financing at $5.25 on January 14th and trading at discount at $4.40. Oversold on the daily (RSI @ 28). Accum/Dist is evening out after 3 days of selloff. Gap at 6.41. Cash + assets exceed current market cap.